PDZ-Binding Kinase-Dependent Transcriptional Regulation of CCNB2 Promotes Tumorigenesis and Radio-Resistance in Glioblastoma.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
14
08
2019
revised:
25
09
2019
accepted:
25
09
2019
pubmed:
25
12
2019
medline:
25
12
2019
entrez:
25
12
2019
Statut:
ppublish
Résumé
Increasing evidence has indicated that PDZ binding kinase (PBK) promotes proliferation, invasion, and therapeutic resistance in a variety of cancer types. However, the physiological function and therapy-resistant role of PBK in GBM remain underexplored. In this study, PBK was identified as one of the most therapy-resistant genes with significantly elevated expression level in GBM. Moreover, the high expression level of PBK was essential for GBM tumorigenesis and radio-resistance both in vitro and in vivo. Clinically, aberrant activation of PBK was correlated with poor clinical prognosis. In addition, inhibition of PBK dramatically enhanced the efficacy of radiation therapy in GBM cells. Mechanically, PBK-dependent transcriptional regulation of CCNB2 was critical for tumorigenesis and radio-resistance in GBM cells. Collectively, PBK promotes tumorigenesis and radio-resistance in GBM and may serve as a novel therapeutic target for GBM treatment.
Identifiants
pubmed: 31874375
pii: S1936-5233(19)30437-1
doi: 10.1016/j.tranon.2019.09.011
pmc: PMC6931196
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
287-294Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Autophagy. 2019 Aug;15(8):1487-1488
pubmed: 31117874
Science. 2018 Dec 21;362(6421):1416-1422
pubmed: 30573629
Cancer Lett. 2019 Jun 28;452:90-102
pubmed: 30914208
Mol Pharm. 2018 Aug 6;15(8):3216-3226
pubmed: 29902012
J Clin Oncol. 2008 Jun 20;26(18):3015-24
pubmed: 18565887
Cancer Res. 2018 Feb 15;78(4):853-864
pubmed: 29233929
Cell. 2018 May 31;173(6):1413-1425.e14
pubmed: 29754815
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9
pubmed: 23650391
Int J Oncol. 2018 Aug;53(2):801-814
pubmed: 29901068
Arch Med Res. 2019 Jan;50(1):10-17
pubmed: 31101236
Science. 2016 Jul 22;353(6297):399-403
pubmed: 27463676
Molecules. 2017 Dec 05;22(12):
pubmed: 29206199
Oncogene. 2010 Oct 7;29(40):5464-74
pubmed: 20622899
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Oncogene. 2012 May 10;31(19):2389-400
pubmed: 21996732
BMC Cancer. 2013 Jan 02;13:1
pubmed: 23282137
Cancer Sci. 2017 Mar;108(3):488-496
pubmed: 28075524
Biomed Pharmacother. 2015 Aug;74:222-7
pubmed: 26349989
J Clin Oncol. 2009 Mar 10;27(8):1275-9
pubmed: 19188675
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
J Ginseng Res. 2016 Oct;40(4):400-408
pubmed: 27746693
Oncogene. 2019 Feb;38(7):1136-1150
pubmed: 30237440
Cancer Cell. 2016 Apr 11;29(4):563-573
pubmed: 27070703
Clin Cancer Res. 2018 Jul 15;24(14):3409-3422
pubmed: 29599413
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5167-72
pubmed: 10779557
Oncol Rep. 2015 Dec;34(6):3288-96
pubmed: 26503118
Science. 2016 Aug 26;353(6302):929-32
pubmed: 27563096
Clin Cancer Res. 2009 Dec 15;15(24):7510-7518
pubmed: 20008851
Cancer Cell Int. 2015 Feb 28;15:27
pubmed: 25745361
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Clin Cancer Res. 2016 Dec 15;22(24):6110-6117
pubmed: 27334838
J Neurooncol. 2019 Jan;141(2):315-325
pubmed: 30460633
Cancer Lett. 2019 Mar 31;445:11-23
pubmed: 30590102
Cell Signal. 2017 Nov;39:74-83
pubmed: 28780319
Mol Cancer. 2015 Jun 17;14:121
pubmed: 26081429